Related Experiment Video
Updated: Mar 27, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
[Non-coding RNAs in castration-resistant prostate cancer]
Abstract:
Non-coding RNAs (ncRNAs) are a large class of RNA molecules that do not encode proteins, regulate gene expressions multifacetedly, and influence the metabolism, proliferation, differentiation and apoptosis of cells as well as the occurrence and progression of tumors. Some of the ncRNAs act as cancer genes, such as miR-19a, miR-125b, miR-616, miR-7, miR-221, MALAT-1, and PRNCR1, which are upregulated in castration-resistant prostate cancer (CRPC) tissues or cell lines, and promote the development and progression of CRPC, some act as tumor suppressor genes, including miR-185, miR-342, miR-15, miR-16, and miR-146, which are downregulated in CRPC tissues or cell lines and inhibit or delay the occurrence of CRPC, and still others, such as miR-7, miR-19a, miR-125b, miR-221, and MALAT-1, are differentially expressed in the serum or tissue and can be used as potential biomarkers for the early diagnosis and prognosis of CRPC. This article presents an overview on the roles of ncRNAs in the occurrence, progression, diagnosis, and prognosis of CRPC and advances in their studies.
Insights
Non-coding RNAs (ncRNAs) play crucial roles in cancer. This review explores how ncRNAs influence castration-resistant prostate cancer (CRPC) development, progression, and potential as diagnostic biomarkers.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Non-coding RNAs (ncRNAs) are critical regulators of gene expression.
- ncRNAs significantly impact cellular processes including metabolism, proliferation, differentiation, and apoptosis.
- Dysregulation of ncRNAs is implicated in tumor occurrence and progression.
Purpose of the Study:
- To provide an overview of the multifaceted roles of ncRNAs in castration-resistant prostate cancer (CRPC).
- To discuss the involvement of ncRNAs in the occurrence, progression, diagnosis, and prognosis of CRPC.
- To highlight recent advancements in the study of ncRNAs in CRPC.
Main Methods:
- Literature review and synthesis of existing research on ncRNAs in CRPC.
- Analysis of specific ncRNAs acting as oncogenes or tumor suppressors in CRPC.
- Examination of ncRNAs as potential biomarkers for CRPC diagnosis and prognosis.
Main Results:
- Certain ncRNAs (e.g., miR-19a, MALAT-1) are upregulated in CRPC and promote its progression.
- Other ncRNAs (e.g., miR-185, miR-15) are downregulated in CRPC and act as tumor suppressors.
- Differentially expressed ncRNAs (e.g., miR-7, miR-221) show potential as biomarkers for CRPC early diagnosis and prognosis.
Conclusions:
- ncRNAs are key players in the pathogenesis of CRPC, acting as both oncogenes and tumor suppressors.
- The dysregulation of specific ncRNAs contributes to CRPC development and progression.
- ncRNAs hold significant promise as diagnostic and prognostic biomarkers for CRPC.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Experimental RNAi
MicroRNAs
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

